DK0559632T3 - Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor - Google Patents

Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor

Info

Publication number
DK0559632T3
DK0559632T3 DK93870037T DK93870037T DK0559632T3 DK 0559632 T3 DK0559632 T3 DK 0559632T3 DK 93870037 T DK93870037 T DK 93870037T DK 93870037 T DK93870037 T DK 93870037T DK 0559632 T3 DK0559632 T3 DK 0559632T3
Authority
DK
Denmark
Prior art keywords
tfpi
purifying
exchange chromatography
sulfonate
refolding
Prior art date
Application number
DK93870037T
Other languages
Danish (da)
English (en)
Inventor
Judith Arlene Diaz-Collier
Mark Edward Gustafson
Tze-Chein Wun
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Application granted granted Critical
Publication of DK0559632T3 publication Critical patent/DK0559632T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK93870037T 1992-03-02 1993-03-01 Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor DK0559632T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/844,297 US5212091A (en) 1992-03-02 1992-03-02 Method of producing tissue factor pathway inhibitor

Publications (1)

Publication Number Publication Date
DK0559632T3 true DK0559632T3 (da) 1998-10-26

Family

ID=25292320

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93870037T DK0559632T3 (da) 1992-03-02 1993-03-01 Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor

Country Status (7)

Country Link
US (1) US5212091A (de)
EP (1) EP0559632B1 (de)
JP (1) JP3333846B2 (de)
AT (1) ATE169957T1 (de)
CA (1) CA2090650C (de)
DE (1) DE69320389T2 (de)
DK (1) DK0559632T3 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5849703A (en) * 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
GB9215541D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3779728B2 (ja) * 1994-08-05 2006-05-31 カイロン コーポレイション 組織因子活性インヒビターの産生
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
DE69635051T2 (de) 1995-06-07 2006-06-14 Chiron Corp Methode zur lösung, reinigung und rückfaltung von protein
AU2003200506B2 (en) * 1995-06-07 2007-01-18 G.D. Searle Llc Method of solubilizing, purifying and refolding protein and compositions comprising proteins and solubilizing agents
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5824660A (en) * 1996-06-10 1998-10-20 G. D. Searle & Co. Method of inhibiting glomerulonephritis
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
AU781717B2 (en) * 1998-04-24 2005-06-09 Csl Behring Gmbh Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography
US6794159B1 (en) 1999-04-30 2004-09-21 Pharmacia Corporation Method of removing n-terminal alanine residues from polypeptides with aeromonas aminopeptidase
US6743600B1 (en) 1999-04-30 2004-06-01 Monsanto Technologies Llc Method of removing N-terminal alanine residues from polypeptides with Aeromonas aminopeptidase
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
EP1446140A4 (de) * 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic Behandlung der schweren pneumonie durch verabreichung von tfpi (tissue factor pathway inhibitor)
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
WO2005019265A1 (en) * 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. INHIBITION PROTEAZE
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
KR101179171B1 (ko) 2008-08-14 2012-09-03 주식회사 운화 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 간질환의 예방 또는 치료용 조성물
CA2744235A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8088599B2 (en) * 2009-02-06 2012-01-03 Fudan University Nucleic acids encoding genetically modified tissue factor pathway inhibitor (TFPI) and method of making the same
EP3459564B1 (de) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasmakallikreinbindende proteine
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US12528880B2 (en) 2020-01-13 2026-01-20 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421685A (en) * 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US4656249A (en) * 1982-06-10 1987-04-07 Howard Florey Institute Of Experimental Physiology And Medicine Peptides with relaxin activity
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
DE3832898A1 (de) * 1988-09-28 1990-04-12 Boehringer Mannheim Gmbh Praeparat von in prokaryonten exprimiertem plasminogenaktivator
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
AU4408493A (en) * 1992-06-11 1994-01-04 Washington University Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders

Also Published As

Publication number Publication date
EP0559632A3 (de) 1995-03-29
JPH07274968A (ja) 1995-10-24
EP0559632A2 (de) 1993-09-08
ATE169957T1 (de) 1998-09-15
US5212091A (en) 1993-05-18
CA2090650C (en) 2008-01-29
JP3333846B2 (ja) 2002-10-15
EP0559632B1 (de) 1998-08-19
DE69320389T2 (de) 1999-03-11
CA2090650A1 (en) 1993-09-03
DE69320389D1 (de) 1998-09-24

Similar Documents

Publication Publication Date Title
DK0559632T3 (da) Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor
DE3783273T2 (de) Methode fuer das zusammensetzen einer kette.
ATE152172T1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
KR960703433A (ko) 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
HK8694A (en) Topical compositions comprising 11,28-dioxa-4-azatricyclo [22.3.1.0(4,9)] octacos-18-ene derivatives
MY103892A (en) Interleukin-2 of high purity production and use
EP0132732A3 (en) Homologues from aprotinine whose lys 15 amino acid is substituted by other amino acids, process for their preparation and their use as medicaments
FR2562539B1 (fr) Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
DE3485488D1 (de) Imidazoliumsalze, zwischenprodukte fuer ihre herstellung sowie ihre verwendung.
IT1219874B (it) Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
FI931332A0 (fi) Uusia alkyleenidiammoniumdiklavulanaattijohdannaisia, menetelmä niidenvalmistamiseksi samoin kuin niiden käyttö kalvulaanihapon puhdistamiseksi
BR8803293A (pt) Amidas de acido 6,7-dihidro-pirazolo(1,5-a arroba(1,3,5 arroba triazin-2-sulfonico,processo para sua preparacao,composicao herbicida e reguladora do crescimento de plantas,aplicacao e processo para preparacao da composicao
DK134889A (da) Overfladeaktive forbindelser og fremgangsmaade til fremstilling deraf
FI854926A0 (fi) Foerfarande foer framstaellning av farmakologiskt aktiva pyrrolobensimidazoler.
ES2093031T3 (es) Metodo para purificar el factor de crecimiento transformante (tgf).
DK102892A (da) Purin-derivater, farmaceutisk praeparat omfattende forbindelserne samt forbindelser til brug som mellemprodukter
AU604418B2 (en) Cosmetic composition
JPS6456699A (en) Method for obtaining alpha 1-antitrypsin concentrate from human plasma and its utilization as drug
EP0199568A3 (en) Method for purifying interferon and composition of matter produced thereby
IT1222427B (it) Procedimento per la purificazione di interferone
DE68928634D1 (de) Verfahren zur Herstellung von aktivierten Killer-Monozyten und Verfahren zur Überprüfung ihrer tumoriziden Aktivität
EP0241136A3 (de) Humaner, Klasse 1 Heparin bindender, Wachstumsfaktor
FR2684988B1 (fr) Procede industriel de synthese de l'acide hydroxy-10-decene-e-ouique et de l'acide oxo-9-decene-2-ouique, principe actifs de la gelee royale.
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
ITRM950589A0 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire malattie causate dalla sovrapproduzione di dette citochine naturali, e composizioni farmaceutiche cosi' ottenibili